CancerVax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Vaccine Targeting Milestone
May 21 2024 - 3:00AM
CancerVax, Inc., the developer of breakthrough cancer drugs that
will use the body’s immune system to fight cancer, today announced
that its UCLA research team has achieved a critical milestone by
creating a process to add any antibody to lipid nanoparticles (LNP)
using “click chemistry”, for targeting cancer cells.
Click chemistry is a revolutionary approach to chemical
synthesis that won the Nobel Prize in Chemistry 2022. It is
characterized by high efficiency, high reliability, and simplicity
in making precise molecular structures, such as LNPs, quickly and
cost-effectively. In other words, you “click” together what you
need and not anything else. The current approach to manufacturing
LNPs uses imprecise melamine chemistry where unwanted materials end
up in the final product, leading to toxicity and low
efficiency.
The LNP is the vehicle that carries the functional cargoes of
the Company’s Universal Cancer Vaccine (“UCV”) to precisely detect,
mark and kill cancer cells. UCV uses multiple targeting signals to
detect cancer cells with precision, as opposed to the conventional
single signal targeting. By using click chemistry, the UCLA team
has successfully created a customizable precision LNP architecture
where various antibodies can be “clicked” onto the outside. These
antibodies only bind to matching proteins (aka antigens) on the
cancer cell surface like a lock-and-key mechanism. Once attached to
the cell surface, the LNP would then enter the cancer cell and
release additional UCV molecules that perform additional matching
inside the cell to confirm that the cell is in fact a cancer cell.
This multi-signal targeting is the very foundation of UCV’s high
precision targeting of cancer cells.
CancerVax CEO, Byron Elton, said, “We believe that precision
targeting of cancer cells is vital to better patient outcome and
higher quality of care. Previous generations of cancer treatments
such as chemotherapy, radiation, surgery and even other cancer
vaccines are not that precise – as many people already know.
Our UCV is a revolutionary concept. It is an outside the box
approach that leverages state-of-the-art bioengineering and
molecular technologies to develop a better way to treat cancer, by
precisely detecting, marking, and killing cancer cells. The
UCLA team continues to tell us that they are very excited about
this ‘fresh-thinking’ approach and are working tirelessly to
advance the development of our Universal Cancer Vaccine
platform.”
About Us
CancerVax, Inc. is a pre-clinical biotechnology company
developing breakthrough cancer drugs that will use the body’s
immune system to fight cancer. Working with a team of world class
cancer researchers and oncologists at UCLA, we intend to create a
Universal Cancer Vaccine that will detect, mark, and destroy only
the diseased cells with incredible precision. Like the COVID-19
vaccines that train the body to recognize and destroy the
coronavirus, our cancer vaccine will leverage the body’s immune
system to destroy cancer cells. Also working with UCLA, we have
created our first cancer drug candidate – a single-disease specific
immunotherapy targeting Ewing sarcoma, a rare but deadly bone and
soft tissue cancer primarily affecting children and young adults.
Based on the positive data, we plan to launch FDA IND enabling
studies needed to apply for approval to proceed with human trials.
We look forward to the day when treating cancer will be as simple
as getting a flu shot – a better way to treat cancer. To learn
more, please visit www.CancerVax.com
Forward-Looking Statements
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business,
plans and strategies, projections, anticipated events and trends,
the economy, and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that are
difficult to predict, many of which are outside our control. Our
actual results and financial condition may differ materially from
those in the forward-looking statements. Therefore, you should not
rely on any of these forward-looking statements. Any
forward-looking statement made by us in this release is based only
on information currently available to us and speaks only as of the
date it is made. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments, or otherwise.
Press Contact: CancerVax, Inc. Tel: (805) 356-1810
communications@CancerVax.com